Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/26/2023 | -3.9% | Citigroup | $7 → $8 | Maintains | Sell |
06/16/2023 | -15.92% | Citigroup | $8.25 → $7 | Downgrades | Neutral → Sell |
06/02/2023 | -9.91% | Susquehanna | $8 → $7.5 | Maintains | Neutral |
05/02/2023 | -0.9% | Citigroup | $8.5 → $8.25 | Maintains | Neutral |
04/27/2023 | -3.9% | Susquehanna | $8.5 → $8 | Maintains | Neutral |
04/03/2023 | 2.1% | Susquehanna | $10.5 → $8.5 | Maintains | Neutral |
03/14/2023 | 500.6% | Susquehanna | → $50 | Reiterates | → Neutral |
10/27/2022 | 26.13% | Susquehanna | $8 → $10.5 | Maintains | Neutral |
04/28/2022 | 56.16% | Johnson Rice | → $13 | Upgrades | Hold → Accumulate |
03/25/2021 | -51.95% | Morgan Stanley | $3.5 → $4 | Maintains | Underweight |
11/10/2020 | -69.97% | Morgan Stanley | → $2.5 | Downgrades | Equal-Weight → Underweight |
08/26/2020 | -66.37% | Citigroup | $2.3 → $2.8 | Maintains | Sell |
07/08/2020 | -63.96% | Morgan Stanley | $2.5 → $3 | Maintains | Equal-Weight |
05/28/2020 | -62.76% | Piper Sandler | $2.8 → $3.1 | Maintains | Neutral |
05/21/2020 | -72.37% | Citigroup | $1.9 → $2.3 | Maintains | Sell |
05/07/2020 | -51.95% | Raymond James | $3 → $4 | Reiterates | → Outperform |
04/06/2020 | -77.78% | Piper Sandler | $1.4 → $1.85 | Maintains | Neutral |
03/16/2020 | -69.97% | Morgan Stanley | $6 → $2.5 | Downgrades | Overweight → Equal-Weight |
01/06/2020 | — | Raymond James | Upgrades | Market Perform → Outperform | |
11/20/2019 | — | Citigroup | Downgrades | Neutral → Sell | |
10/24/2019 | -57.96% | Wells Fargo | $4 → $3.5 | Maintains | Underperform |
10/21/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
10/09/2019 | -42.34% | Citigroup | $5 → $4.8 | Maintains | Sell |
10/07/2019 | -15.92% | Morgan Stanley | $8 → $7 | Maintains | Overweight |
09/30/2019 | -39.94% | Barclays | $5.5 → $5 | Maintains | Underweight |
09/23/2019 | -39.94% | Citigroup | $5.5 → $5 | Maintains | Sell |
09/12/2019 | -45.95% | Wells Fargo | $5.5 → $4.5 | Maintains | Underperform |
07/25/2019 | — | Gabelli & Co. | Downgrades | Buy → Hold | |
07/12/2019 | 20.12% | Morgan Stanley | $15 → $10 | Maintains | Overweight |
04/25/2019 | 14.11% | Morgan Stanley | $12 → $9.5 | Reiterates | → Underperform |
04/04/2019 | 80.18% | Morgan Stanley | $11 → $15 | Upgrades | Underweight → Overweight |
03/11/2019 | 20.12% | Goldman Sachs | → $10 | Initiates Coverage On | → Sell |
01/29/2019 | 80.18% | Seaport Global | → $15 | Upgrades | Neutral → Buy |
01/15/2019 | -3.9% | Barclays | $13 → $8 | Downgrades | Equal-Weight → Underweight |
01/10/2019 | -3.9% | Citigroup | $11 → $8 | Downgrades | Neutral → Sell |
01/09/2019 | — | Citigroup | Downgrades | Neutral → Sell | |
12/13/2018 | — | Raymond James | Downgrades | Market Outperform → Market Perform |
What is the target price for RPC (RES)?
The latest price target for RPC (NYSE: RES) was reported by Citigroup on October 26, 2023. The analyst firm set a price target for $8.00 expecting RES to fall to within 12 months (a possible -3.90% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RPC (RES)?
The latest analyst rating for RPC (NYSE: RES) was provided by Citigroup, and RPC maintained their sell rating.
When is the next analyst rating going to be posted or updated for RPC (RES)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RPC, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RPC was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
Is the Analyst Rating RPC (RES) correct?
While ratings are subjective and will change, the latest RPC (RES) rating was a maintained with a price target of $7.00 to $8.00. The current price RPC (RES) is trading at is $8.32, which is out of the analyst's predicted range.